Table 2 Baseline demographics and visual acuity of the eyes diagnosed with wet AMD and treated with either Ranibizumab, Aflibercept or Bevacizumab
Baseline | Ranibizumab | Aflibercept | Bevacizumab | P |
|---|---|---|---|---|
Number of eyes (patients) | 373 (336) | 457 (412) | 35 (32) | - |
Age (years, mean) | 85.5 (± 8.65) | 82.7 (± 10.40) | 71.9 (± 19.04) |  < 0.0001 |
Sex—male (%) | 149 (39.9%) | 191 (41.8%) | 13 (37.1%) | 0.74 |
Best Corrected Visual Acuity (BCVA, LogMAR) | 0.59 (± 0.22) | 0.56 (± 0.21) | 0.62 (± 0.46) | 0.53 |